Parvoviruses and blood products

Laub, R; Strengers, P. F. W.

doi:10.1016/s0369-8114(02)00303-6

Cited by 39 publications

(33 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…B19 virus infection is common, and 40% to 60% of adults have antibodies against the virus due to previous exposure. Epidemiologically, infection rates increase every three to four years, but there can be longer cycles, with viral activity increasing every four to seven years [16][17][18]. The overall prevalence of IgG antibodies to parvovirus B19 in healthy adults is 50% in the United States and Japan [19,20]; 60%-70% in England and Wales [21]; 50% in India [22]; and 53.2% in Spain [23].…”

Section: Discussionmentioning

confidence: 99%

Molecular and serological assessment of parvovirus B19 infections among sickle cell anemia patients

Obeid

2011

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: Parvovirus B19 is a cause of hemolysis and red blood cell aplasia in patients with sickle cell anemia. The present study aimed to assess parvovirus B19 infection among sickle cell anemia patients. Methodology: All patients (n = 138) included in the study were sickle cell anemia patients. Blood donors were used as a control group. Assessment of parvovirus B19 antibodies and viral DNA was performed using established methods of detection and B19 recomBlot assay. Results: Detectable levels of parvovirus B19 IgG were found in 52 samples (37.6%) whereas anti-parvovirus B19 IgM antibodies were detected in four (2.89 %) patients of the sickle-cell anemia group. Anti-B19 IgM-positive samples contained B19-viral DNA. These four patients presented with fever, malaise, pallor and no cutaneous rash. Anti-parvovirus B19 antibodies were detected in 22 (39.3%) of the control blood donors group. Anti-parvovirus B19 IgM antibodies were not detected in the control group. Using the recomBlot assay, 58 test samples (42%) were found to contain detectable levels of Parvovirus B19 antibodies. All the samples that were positive for parvovirus B19 IgG by the ELISA were also positive by the recomBlot assay. Six samples were only positive by the recomBlot assay and not by the ELISA. Two of these six samples were positive for B19 viral DNA. Conclusions: Establishing the extent of parvovirus B19 infection in sickle cell anemia patients will help in proper management of aplastic crisis in such patients. The B19 recomBlot assay may be suitable as a confirmatory assay.

show abstract

Section: Discussionmentioning

confidence: 99%

Molecular and serological assessment of parvovirus B19 infections among sickle cell anemia patients

Obeid

2011

J Infect Dev Ctries

View full text Add to dashboard Cite

show abstract

“…Erythrovirus (formerly parvovirus) B19 and the novel Erythrovirus V9 are by now the only parvoviruses implied in human disease (Laub & Strengers 2002). Their genomes consist both of single-stranded DNA molecules 5596 nucleotides long.…”

mentioning

confidence: 99%

“…Their genomes consist both of single-stranded DNA molecules 5596 nucleotides long. They diverge by 11%, mainly in the VP1 capsid gene (Nguyen et al 1999, Laub & Strengers 2002. There seems to be no cross immunity between them (Nguyen et al 1999).…”

mentioning

confidence: 99%

“…Epidemiologically, rates of infection increase every 3-4 years (Serjeant et al 1993), although longer cycles, with increases in viral activity occurring every 4-7 years (Rodis 1999), have also been described. B19 is usually spread by respiratory secretions, but can be transmitted transplacentally and by transfusion of blood or blood components (Laub & Strengers 2002).…”

mentioning

confidence: 99%

“…Although it is less frequent, single donor blood components (e.g., platelets) can also transmit B19 infection (Cohen et al 1997). In spite of this, blood donor units are not screened routinely for non-enveloped viruses such as B19 (Laub & Strengers 2002). Screening by very sensitive tests like PCR may be impractical due to many false positive results related to low level (and less infective) viremia.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Viremic blood donor found by a rapid screening method in a season of high human parvovirus B19 activity in Niterói, Rio de Janeiro, Brazil

Setúbal

Cárdias

Oliveira

et al. 2004

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

show abstract

Parvovirus B19 infection in chile: Markers of infection and immunity in patients with clinical symptoms

Larrañaga

León

Díaz

et al. 2007

Journal of Medical Virology

View full text Add to dashboard Cite

Parvovirus B19 infection is associated with a wide variety of symptoms and signs, and given that some clinical features, such as anemia, arthropathy and rash may be attributable to other causes, laboratory diagnosis of B19 markers is necessary. The principal aims were to study the behavior of B19 infection-associated diseases in the Chilean population and to compare B19 markers for recent or active infection and for immunity status in patients with clinical symptoms suspicious of B19 infection and control individuals. Sera from a total of 267 patients with diverse clinical manifestations associated with B19 and from 69 healthy controls were tested for B19 DNA using PCR and for specific IgM and immunoglobulin G (IgG) by enzyme-linked immunosorbent assay (ELISA). Out of 267 patients examined, 89 had B19-associated disease markers: 43 had B19 DNA without IgM, 25 had IgM without B19 DNA, and 21 had both B19 DNA and IgM. Also 49 patients were positive only for IgG without B19 DNA or IgM. Out of the 69 healthy controls, only 2 had B19 DNA without IgM and 30 had IgG without B19 DNA and/or IgM. The distribution of the clinical diagnoses associated with recent B19 infection, tested by B19 DNA and/or IgM, included 38.5% with hematological illnesses, 23.4% with rheumatic diseases, 45.7% with infectious diseases, 33.3% with indications of prenatal infection, 32.3% with conditions that induce immunodeficiency, and 15.8% with other miscellaneous conditions. The use of both markers, DNA and IgM, allows a more adequate diagnosis of infection by this virus.

show abstract

Parvoviruses and blood products

Cited by 39 publications

References 82 publications

Molecular and serological assessment of parvovirus B19 infections among sickle cell anemia patients

Molecular and serological assessment of parvovirus B19 infections among sickle cell anemia patients

Viremic blood donor found by a rapid screening method in a season of high human parvovirus B19 activity in Niterói, Rio de Janeiro, Brazil

Parvovirus B19 infection in chile: Markers of infection and immunity in patients with clinical symptoms

Contact Info

Product

Resources

About